Miltuximab® for Therapeutics and Imaging

Our patented antibody targets Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, esophageal and other solid tumors.

We have commenced a first in human trial using Miltuximab®, our anti-GPC-1 monoclonal antibody (ANZCTR registry).

The MILGa Cancer Imaging Trial is a first-in-human study to evaluate the safety and tumor targeting of Miltuximab® in patients with advanced prostate, bladder and pancreatic cancer. Preclinical studies have demonstrated that Miltuximab® accurately targets prostate, pancreatic and bladder cancer cells, and is well-tolerated and highly specific in mouse models of prostate cancer.

The trial being conducted at the Macquarie University Hospital also involves experts from the Australian Nuclear Science and Technology Organisation (ANSTO), Catalent, AusPep, and Southern Star Research. Read more >

In October 2016 Minomic announced the start of our first in-human trial using Miltuximab® conjugated to the radioactive isotope 67Gallium and we have now dosed a total of 6 patients with no adverse reactions whatsoever.

In addition to radiotherapy, Minomic is looking at other mechanisms of action using Miltuximab®

Global research collaborations

Minomic’s collaborations are advancing trials of prostate cancer diagnostics, therapeutics, and imaging as well as building a future product pipeline.

For example:

  • The Centre for Advanced Imaging at the University of Queensland
  • The Australian Prostate Cancer Research Centre at the Queensland University of Technology
  • The IDEAL Hub, University of Technology Sydney and University of South Australia
  • The Division of Urologic Oncology at the University of Michigan Medical School
  • Molecular Imaging Innovations Institute at Weill Cornell Medical College New York
Talk with us about combining Miltuximab® with other therapies in your product portfolio. Contact us >